TipRanks
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market
CTNM
Contineum Therapeutics, Inc. Class A
RESEARCH TOOLSreports
Want to see CTNM full AI Analyst Report?

Contineum Therapeutics, Inc. Class A (CTNM) Stock News & Sentiment

227 Followers
Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial
Premium
Ratings
Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial
12d ago
CTNM
Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver
Premium
Ratings
Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver
27d ago
CTNM
Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback
Premium
Ratings
Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback
27d ago
CTNM
Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results
Premium
Company Announcements
Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results
27d ago
8K
CTNM
Contineum Therapeutics: Buy Rating Reiterated with PIPE-791 Upside Potential and Unchanged $26 Price Target
Premium
Ratings
Contineum Therapeutics: Buy Rating Reiterated with PIPE-791 Upside Potential and Unchanged $26 Price Target
1M ago
CTNM
Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
Premium
Ratings
Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
2M ago
CTNM
Analyst Initiates Buy on Contineum, Citing PIPE-791’s Differentiated IPF Profile and Favorable Risk-Reward Ahead of Key 2026 Readthrough
Premium
Ratings
Analyst Initiates Buy on Contineum, Citing PIPE-791’s Differentiated IPF Profile and Favorable Risk-Reward Ahead of Key 2026 Readthrough
2M ago
CTNM
More CTNM News >

CTNM News on the Web

Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial
TipRanks News
Bullish
Contineum Therapeutics Inc trading halted, volatility trading pause
TipRanks News
Bearish
Contineum price target lowered to $17 from $18 at Morgan Stanley
TipRanks News
Neutral
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading
TipRanks News
Bullish
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Insider Monkey
Bearish
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
TipRanks News
Bullish
Contineum Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average7.5 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CTNM’s Media Buzz Sentiment?
Currently, no data Available
What is CTNM’s weekly average amount of articles?
In an average week, 7.5 articles about CTNM are published.
    What is CTNM’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    AMGNAmgen
    GKOSGlaukos
    OVIDOvid Therapeutics
    ABTAbbott Laboratories
    IQVIQVIA Holdings
    Showing the stocks with the most bullish news sentiment over the past week